01—Abstract
Summary
Summary of the 8-K filed August 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) announced on August 3, 2026 a CEO succession.
Julie Sawyer Montgomery, a Danaher executive since 2017 who currently leads the Diagnostics platform as Executive Vice President, will become President and CEO effective October 1, 2026, and will join the Board and its Executive, Finance and Science & Technology Committees. Rainer M. Blair steps down as CEO and director on the same date, moving to a Senior Advisor role through December 31, 2026 and then a consultancy through March 31, 2027.
The filing states there is no change to previously communicated third quarter and full-year 2026 guidance. Compensation for the new CEO is substantial. Her base salary rises to $1.5 milliona, with a 200% target annual cash incentive and a 2027 long-term incentive target of $13.2 million.
She also receives a one-time $20 millionb stock option award (ten-year term, 50% vesting at years four and five), and her severance package includes 12 months of salary plus target bonus amounts. Chairman Steven Rales and Mitchell Rales, co-founders, also received special option and RSU grants (1,000,000 options and 500,000 RSUs each) under a Long-Term Growth Program. The company expects to exclude the stock-based compensation expense for this program from Adjusted Diluted EPS, which is a notable point for investors reviewing non-GAAP earnings.
For investors, the key items are continuity of the Diagnostics-led strategy, an orderly transition with Blair remaining available through the advisory period, and the scale of equity incentives tied to long-term growth. Investors should watch execution on the pending StatLab acquisition and the Masimo integration, as well as how the Adjusted EPS exclusion is presented going forward.
02—Key points
Key Highlights
- Julie Sawyer Montgomery named President and CEO effective October 1, 2026, succeeding Rainer M. Blair, who retires as CEO and director.
- Montgomery joins the Board and the Executive, Finance and Science & Technology Committees; she has been with Danaher since 2017 and is currently EVP overseeing the Diagnostics platform.
- New CEO base salary set at $1.5 million, with 200% target annual cash incentive and a 2027 long-term incentive target of $13.2 million.
- One-time $20 million Long-Term Growth Award in time-vesting stock options (50% at year four, 50% at year five, ten-year term) granted August 4, 2026.
- Co-founders Steven and Mitchell Rales receive Long-Term Growth Program awards of 1,000,000 options and 500,000 RSUs each, subject to the same vesting schedule.
- Blair transitions to Senior Advisor through December 31, 2026, then a consultant through March 31, 2027, with severance of 12 months' salary, target bonus, and a COBRA subsidy.
- Management states no change to Q3 and full-year 2026 guidance, and the Long-Term Growth Program stock-based compensation will be excluded from Adjusted Diluted EPS.
03—Questions
Frequently Asked Questions
Does this CEO change affect Danaher's 2026 financial guidance?
No. The company states there is no change to its previously communicated third quarter and full-year 2026 guidance, in both the 8-K and the press release.
Who is the new CEO and what is her background?
Julie Sawyer Montgomery, age 54, joined Danaher in 2017 at Beckman Coulter Diagnostics, served as its President from 2020 to 2022, led Diagnostics as Vice President-Group Executive from 2023 to mid-2024, and has been an Executive Vice President since July 2024. The press release credits her with growing Diagnostics from roughly $6.0 billion in 2017 revenue to about $11.0 billion today and leading the Masimo acquisition and the pending StatLab deal.
How large is the new CEO's compensation package?
Her package includes a $1.5 million base salary, a 200% target cash bonus, a 2027 LTI target of $13.2 million, and a one-time $20 million option award. Severance on termination without cause or for good reason is 12 months' salary plus target bonus amounts, subject to a release and a restated non-compete.
Why does the Long-Term Growth Program matter for investors?
The awards are large, with options and RSUs tied to the CEO and co-founders, and vest over four to five years. The company will exclude their stock-based compensation expense from Adjusted Diluted EPS, so investors should compare GAAP and adjusted results closely as these costs are recognized.
What happens to Rainer Blair after the transition?
Blair remains a non-officer employee as Senior Advisor through December 31, 2026, keeps his base salary and equity vesting, and is eligible for a full 2026 annual bonus at 100% personal payout. He then serves as a consultant at his monthly salary rate through March 31, 2027, with no bonus or equity eligibility. He receives 12 months' base salary, his target bonus, and a COBRA subsidy at separation, subject to releases.
04—Continue